Project Grant R21AG104396
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $902K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- The National Institute on Aging awarded CAL Poly Humboldt Sponsored Programs Foundation $267,525 on September 5, 2026, under the Aging Research program (CFDA 93.866) to conduct systems biology research investigating the role of klotho and estrogen in combating neurodegeneration associated with Alzheimer's disease. The project applies ordinary differential equations and agent-based modeling to simulate molecular signaling cascades, cellular metabolic reprogramming, and spatial microenvironment...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded The Regents of the University of California, San Francisco $194,573 on February 20, 2026, under the Aging Research program (CFDA 93.866) to investigate mechanisms of microglial-mediated sex-based differences in tauopathy. The recipient will conduct basic research examining how gonadal hormones contribute to sex-based differences in tau-related neurodegeneration through their effects on microglia, the...
- The National Institute on Aging awarded Rosalind Franklin University of Medicine & Science $696,253 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate how hormonal fluctuations during perimenopause alter hippocampal neural circuits and accelerate Alzheimer's disease pathology in female mice. The recipient will use 4-vinylcyclohexene diepoxide (VCD) to chemically induce ovarian failure in AppNLGF knock-in AD model mice, mimicking human perimenopause...
- The National Institute on Aging awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $189,963 on July 1, 2026, under the Aging Research program (CFDA 93.866) to support research led by Dr. Carlisle investigating the contributions of biological sex and sex hormones to cognitive reserve across the cognitive spectrum of Alzheimer's disease. The research will assess how estrogen and sex differences affect Alzheimer's disease risk, with particular...
- The National Institute on Aging awarded New York University School of Medicine $3,557,115 on August 5, 2026, under the Aging Research program (CFDA 93.866) to investigate the neurobiological mechanisms linking menopause and cognitive decline in women. The recipient will conduct a longitudinal study mapping neurobiological changes during the menopause transition in a cohort of 120 pre- and perimenopausal women aged 40–48 using state-of-the-art neuroimaging, plasma proteomics, and clinical...
- The National Institute on Aging awarded the University of Southern California $149,190 on August 6, 2026, under the Aging Research program (CFDA 93.866) to investigate how early-stage Alzheimer's disease disrupts coordinated release dynamics between acetylcholine and norepinephrine in the cortex and how this discoordination impairs cognitive performance. The research characterizes the evolution of coordinated cortical acetylcholine and norepinephrine release activity in vivo in wildtype mice,...
- The National Institute on Aging awarded $214,140 to the University of California, Los Angeles on March 18, 2026, under the Aging Research program (CFDA 93.866) to conduct research on estrogenic signaling mechanisms that regulate metabolic response to energy deficit. The research aims to understand how circulating estrogens reduce fasting-induced torpor usage in mice, thereby maintaining high energy expenditure despite dangerous energy deficits—findings relevant to metabolic changes during...
- The National Institute on Aging awarded the University of Southern California $5.945 million on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct the Alzheimer's Risk Intervention Trial with Estradiol (ARITE), a randomized, double-blinded, placebo-controlled investigation of menopausal hormone therapy effects on neuroimaging markers of Alzheimer's disease and related dementias risk in postmenopausal women. The trial enrolls 360 postmenopausal women and uses brain...
- The National Institute on Aging awarded the University of California, San Diego $408,012 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop methods for improving central nervous system pharmacokinetics of targeted protein degraders through specialized assay workflows and prodrug chemistries. The research will establish dual-functional molecules that hijack endogenous molecular transport pathways to cross the blood-brain barrier, with early-stage application to...
- The National Institute on Aging awarded The Regents of the University of California, San Francisco $1,419,145 on June 1, 2026, under the Aging Research program (CFDA 93.866) to conduct cell-type-specific drug repurposing for Alzheimer's disease using single-nucleus transcriptomic profiling and computational drug repositioning. The project employs state-of-the-art single-nucleus transcriptomic analysis (VINE-SEQ) and integrative computational tools including Connectivity Map and LINCS to identify...